Fig. S4.
Expression levels of NICD1 in tumors driven by NICD1 in combination with kRasG12D, myrAKT, or Myc resemble levels of nuclear NICD1 in human CRPC specimens. Levels of nuclear NICD1 overexpression mimic the levels of nuclear NICD1 in human CRPC. Immunohistochemical analyses of 4- μm sections of paraffin-embedded human low- to intermediate-risk prostate cancer (Gleason score 6 or 7), localized high-risk prostate cancer (Gleason score 8–10), CRPC specimens, and NICD1/myrAKT tumors with antibodies against NICD1 (Novus Biologicals) are shown. (Scale bars: 100 microns in left panels; 50 microns in right panels.)